1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Integrin Isoform Specific Products:

  • αvβ1

  • αvβ3

  • αvβ5

  • αvβ6

  • αvβ8

  • α5β1

  • α1β1

  • α2β1

  • α4β1

  • α6β1

  • α9β1

  • αIIbβ3

  • α4β7

  • αLβ2

Integrin 相关产品 (71):

Cat. No. Product Name Effect Purity
  • HY-16141
    Cilengitide Inhibitor 99.32%
    Cilengitide (EMD 121974) 是一种有效的选择性整合素 ανβ3ανβ5 抑制剂。Cilengitide 抑制 ανβ3 和 ανβ5 与玻连蛋白结合,IC50 值分别为 4 和 79 nM。
  • HY-18644
    CWHM-12 Inhibitor 99.65%
    CWHM-12是αV整联蛋白的有效抑制剂,抑制αvβ8αvβ3αvβ6αvβ1IC50 值分别为0.2,0.8,1.5,1.8 nM。
  • HY-P0023
    Cyclo(-RGDfK) Inhibitor >98.0%
    Cyclo(-RGDfK) 是有效,选择性的整合素 αvβ3 抑制剂,其 IC50 值为 0.94 nM。Cyclo(-RGDfK) TFA 通过与细胞表面的 αvβ3 整合素结合,特异性靶向肿瘤微血管和癌细胞。
  • HY-P0122
    iRGD peptide 99.03%
    iRGD peptide 是一种由 9 个氨基酸组成的环肽,先与 av integrins 结合,随后酶解产生 CRGDK/R 与 神经纤毛蛋白-1 (neuropilin-1) 相互作用,从而促进药物的组织渗透,具有靶向肿瘤、肿瘤渗透的作用。
  • HY-14571
    E7820 Inhibitor 99.36%
    E7820 (ER68203-00) 是一种具有口服活性芳香族磺酰胺衍生物,是一种独特的血管生成 (angiogenesis) 抑制剂,可抑制内皮上整合素 α2 (integrin alpha2) 亚基的表达。E7820 抑制大鼠主动脉血管生成,IC50 为 0.11 μg/ml。E7820 调节 α-1,α-2,α-3 和 α-5 整联素 mRNA 表达。具有抗血管生成和抗肿瘤活性。
  • HY-P0023A
    Cyclo(-RGDfK) TFA Inhibitor 99.81%
    Cyclo(-RGDfK) TFA 是有效,选择性的整合素 αvβ3 抑制剂,其 IC50 值为 0.94 nM。Cyclo(-RGDfK) TFA 通过与细胞表面的 αvβ3 整合素结合,特异性靶向肿瘤微血管和癌细胞。
  • HY-W008859
    Tetrac Antagonist
    Tetrac (Tetraiodothyroacetic acid),L-甲状腺素 (T4) 的天然衍生物,是甲状腺素整合素受体拮抗剂。Tetrac 阻断 T4 和 3,5,3'-triiodo-L-thyronine (T3) 在整联蛋白 αvβ3 上甲状腺激素的细胞表面受体处的作用。Tetra 具有抗血管生成和抗肿瘤活性。
  • HY-107589A
    BIO5192 hydrate Inhibitor >98.0%
    BIO5192 hydrate 是一种选择性强的整合素 α4β1 (VLA-4) 抑制剂 (Kd<10 pM)。BIO5192 hydrate 选择性地与 α4β1 (IC50=1.8 nM) 结合,选择性高过其他一系列整合素。BIO5192 hydrate 导致小鼠造血干细胞和祖细胞 (HSPCs) 的动员比基础水平增加 30 倍。
  • HY-100506
    GLPG0187 Antagonist 98.97%
    GLPG0187是广谱的integrin受体拮抗剂,具有抗肿瘤活性;抑制αvβ1-integrin的IC50值为1.3 nM。
  • HY-13535A
    ATN-161 trifluoroacetate salt Antagonist
    ATN-161 trifluoroacetate salt 是一种新型 integrin α5β1 拮抗剂,在肝转移模型小鼠模型中,抑制血管生成。
  • HY-14951
    Firategrast Antagonist 99.66%
    Firategrast (SB 683699) 是一种具有口服活性的,特异性的 α4β1/α4β7 整联蛋白拮抗剂。 Firategrast 减少淋巴细胞进入中枢神经系统 (CNS) 的运输,降低多发性硬化症 (MS) 的活性。
  • HY-15102
    MK-0429 Antagonist 99.73%
    MK-0429 (L-000845704) 是可口服,高效,选择性,非多肽整合素泛拮抗剂,对αvβ1、αvβ3、αvβ5、αvβ6、αvβ8 和 α5β1 的 IC5 0 值分别为1.6 nM、2.8 nM、0.1 nM、0.7 nM、0.5 nM 和 12.2 nM。
  • HY-N0416
    Cucurbitacin B Inhibitor 99.92%
    葫芦素B (Cucurbitacin B)是一具有抗癌活性的天然化合物。
  • HY-18676
    OSU-T315 Inhibitor 99.88%
    OSU-T315 是整联蛋白连接激酶 (ILK) 的抑制剂 (IC50=0.6 μM), 通过去磷酸化 AKT-Ser473 和其他 ILK 靶标 (GSK-3β和肌球蛋白轻链) 抑制 PI3K/AKT 信号传导。 OSU-T315 阻止 AKT 转位到脂筏消除 AKT 的活化,并以 ILK 非依赖性方式触发 Caspase 依赖性细胞凋亡 (Apoptosis)。OSU-T315 通过自噬 (Autophagy) 和凋亡 (Apoptosis) 导致细胞死亡。
  • HY-15701
    Leukadherin-1 Agonist >98.0%
    Leukadherin-1 是特异性的白细胞表面整合素 CD11b/CD18 的激动剂。Leukadherin-1 可增加 CD11b/CD18 依赖性细胞对血纤蛋白原的粘附,EC50为 4 μM。Leukadherin-1 增强白细胞对配体 (如 ICAM-1) 和血管内皮的粘附,从而减少白细胞跨内皮迁移和流入损伤部位。Leukadherin-1 抑制先天性炎症信号转导。
  • HY-12290
    Arg-Gly-Asp-Ser Inhibitor >98.0%
    Arg-Gly-Asp-Ser是整联蛋白结合序列,抑制整联蛋白受体功能,通过抑制胶原蛋白引发的白细胞活化减少全身炎症,并减弱炎性细胞因子,iNOS和MMP-9的表达。
  • HY-15770
    TR-14035 Antagonist
    TR-14035是α4β7/α4β1 integrin拮抗剂,IC50为7 nM和87 nM。
  • HY-P0278A
    RGD Trifluoroacetate >98.0%
    RGD Trifluoroacetate 是一种三肽,能够有效的引起细胞黏着,定位某种特定细胞系并产生特定的细胞反应;RGD Trifluoroacetate 能够与 integrins 结合。
  • HY-19344
    Lifitegrast Antagonist 99.58%
    Lifitegrast (SAR 1118) 是整合素淋巴细胞功能相关抗原-1(LFA-1)的拮抗剂; 抑制Jurkat T细胞附着于ICAM-1IC50为2.98nM。
  • HY-B0686
    Eptifibatide Inhibitor 99.91%
    Eptifibatide 是一种环状七肽,为 glycoprotein IIb/IIIa 受体抑制剂,具有抗血小板活性。
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.